These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 11143836)

  • 1. Re: Managing depression refractory to SSRIs.
    Dewan V
    Can J Psychiatry; 2000 Nov; 45(9):844. PubMed ID: 11143836
    [No Abstract]   [Full Text] [Related]  

  • 2. [Paroxetine augmentation with risperidone in therapy-resistant depression].
    Knopf U; Hubrich-Ungureanu P; Thome J
    Psychiatr Prax; 2001 Nov; 28(8):405-6. PubMed ID: 11721229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder.
    Herrera-Guzmán I; Gudayol-Ferré E; Lira-Mandujano J; Herrera-Abarca J; Herrera-Guzmán D; Montoya-Pérez K; Guardia-Olmos J
    Psychiatry Res; 2008 Jul; 160(1):72-82. PubMed ID: 18501971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.
    Schönfeldt-Lecuona C; Connemann BJ; Wolf RC; Braun M; Freudenmann RW
    Pharmacopsychiatry; 2006 Jul; 39(4):152-4. PubMed ID: 16871471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder.
    Papakostas GI; Worthington JJ; Iosifescu DV; Kinrys G; Burns AM; Fisher LB; Homberger CH; Mischoulon D; Fava M
    Depress Anxiety; 2006; 23(3):178-81. PubMed ID: 16528701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual hallucinations from the addition of riluzole to memantine and bupropion.
    Pittenger C; Naungayan C; Kendell SF; Coric V; Malison R; Krystal JH; Sanacora GS
    J Clin Psychopharmacol; 2006 Apr; 26(2):218-20. PubMed ID: 16633160
    [No Abstract]   [Full Text] [Related]  

  • 7. Should adjunctive antipsychotic treatment be continued in remitted patients with depression?
    Uchida H; Suzuki T; Watanabe K; Kashima H
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):126. PubMed ID: 19154222
    [No Abstract]   [Full Text] [Related]  

  • 8. The combination of buspirone and bupropion in the treatment of depression.
    Fava M
    Psychother Psychosom; 2007; 76(5):311-2. PubMed ID: 17700052
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined antidepressant treatment: a risk factor for switching in bipolar patients.
    Gabbay V; O'Dowd MA; Asnis GM
    J Clin Psychiatry; 2002 Apr; 63(4):367; author reply 367-8. PubMed ID: 12000212
    [No Abstract]   [Full Text] [Related]  

  • 10. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
    Hashimoto K
    J Clin Psychopharmacol; 2009 Aug; 29(4):411-2; author reply 412. PubMed ID: 19593196
    [No Abstract]   [Full Text] [Related]  

  • 11. Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression.
    Park YM; Jung YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 May; 34(4):719-20. PubMed ID: 20298736
    [No Abstract]   [Full Text] [Related]  

  • 12. Open trials in psychiatry: comments on article by Uchida et Al.
    Magalhães PV
    J Clin Psychopharmacol; 2007 Jun; 27(3):318; author reply 318-9. PubMed ID: 17502793
    [No Abstract]   [Full Text] [Related]  

  • 13. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of blonanserin in combination therapy for treatment-resistant depression.
    Kumagai R; Ichimiya Y
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):593-4. PubMed ID: 19659567
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma.
    Kast RE; Altschuler EL
    Med Hypotheses; 2004; 62(5):817-8. PubMed ID: 15082113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bupropion in the management of apathy.
    Corcoran C; Wong ML; O'Keane V
    J Psychopharmacol; 2004 Mar; 18(1):133-5. PubMed ID: 15107198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression.
    Cox LS; Patten CA; Niaura RS; Decker PA; Rigotti N; Sachs DP; Buist AS; Hurt RD
    J Gen Intern Med; 2004 Aug; 19(8):828-34. PubMed ID: 15242467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis.
    Ehde DM; Kraft GH; Chwastiak L; Sullivan MD; Gibbons LE; Bombardier CH; Wadhwani R
    Gen Hosp Psychiatry; 2008; 30(1):40-8. PubMed ID: 18164939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression and association analysis of LIM (PDLIM5) in major depression.
    Iga J; Ueno S; Yamauchi K; Numata S; Motoki I; Tayoshi S; Kinouchi S; Ohta K; Song H; Morita K; Rokutan K; Tanabe H; Sano A; Ohmori T
    Neurosci Lett; 2006 Jun; 400(3):203-7. PubMed ID: 16595163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
    Jamerson BD; Krishnan KR; Roberts J; Krishen A; Modell JG
    Psychopharmacol Bull; 2003; 37(2):67-78. PubMed ID: 14566216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.